Early Phase 1 Lupus Trial, Recruiting NCT07274059 Sponsor: Chengdu Ucello Biotechnology Co., Ltd. Condition: Lupus
Back to Lupus

Early Phase 1 Lupus Trial, Recruiting

NCT07274059
Recruiting Early Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are between 18 and 75 years old (any gender)
  • You have been officially diagnosed with systemic lupus erythematosus (SLE — a type of autoimmune disease) based on recognised medical guidelines
  • Your SLE has not responded well enough to at least 2 standard treatments tried for at least 3 months each
  • Your SLE is currently considered active enough, based on specific medical scoring tools used by your doctor (confirm with trial site)
  • Your bone marrow, liver, kidneys, blood clotting, and heart are functioning at a minimum acceptable level, as measured by blood tests (confirm with trial site)
  • If you are a woman who could become pregnant, you must have a negative pregnancy test within 7 days before joining and agree to use reliable contraception (or abstain) during the study and for at least 6 months after treatment ends, and you must not be breastfeeding
  • If you are a man whose partner could become pregnant, you must also agree to use reliable contraception (or abstain) during the study and for at least 6 months after treatment ends
  • You are willing to take part voluntarily, sign a consent form, and follow the study schedule

Who may not be able to join:

  • You have a history of severe drug allergies or a general tendency toward allergic conditions
  • You currently have, or are suspected to have, an active infection (such as a bacterial, viral, or fungal infection) that is not under control
  • Your heart is not strong enough to handle the study treatment (confirm with trial site)
  • You were born with a condition that means your immune system cannot produce enough antibodies (immunoglobulin deficiency)
  • You have had a cancer diagnosis within the past 5 years
  • Your kidneys have reached end-stage failure
  • You have active hepatitis B, hepatitis C, HIV, or syphilis, based on specific blood test results (confirm with trial site)
  • You have a history of mental illness or severe problems with thinking or memory
  • You have recently taken certain immune-suppressing medications or biological treatments within a specified time before joining (confirm exact timeframes with trial site)
  • You are currently pregnant or planning to become pregnant
  • Your doctor determines there is any other reason you should not take part in the study

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.

Contact this trial

Principal Investigator: Tao Wang, M.D., The General Hospital of Western Theater Command

Phone: +8613550080505

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Early Phase 1
Sponsor
Chengdu Ucello Biotechnology Co., Ltd.
Registry
ClinicalTrials.gov
Start date
26 March 2025
Est. completion
31 December 2035

Where this trial is recruiting

🇨🇳 China

Primary endpoints

the incidence rate of Dose limited toxicity (DLTs); the rate of adverse events

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov